Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor?
Tachibana I, Kern SQ, Douglawi A, Tong Y, Mahmoud M, Masterson TA, Adra N, Foster RS, Einhorn LH, Cary C. Tachibana I, et al. Among authors: douglawi a. Eur Urol. 2023 Jan;83(1):e20-e21. doi: 10.1016/j.eururo.2022.09.018. Epub 2022 Oct 1. Eur Urol. 2023. PMID: 36195478 No abstract available.
Reply by Authors.
Douglawi A, Calaway A, Tachibana I, Panizzutti Barboza M, Speir R, Masterson T, Adra N, Foster R, Einhorn L, Cary C. Douglawi A, et al. J Urol. 2020 Jul;204(1):102-103. doi: 10.1097/JU.0000000000000792.03. Epub 2020 Apr 24. J Urol. 2020. PMID: 32330400 No abstract available.
A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group).
Wu Z, Chen Q, Djaladat H, Minervini A, Uzzo RG, Sundaram CP, Rha KH, Gonzalgo ML, Mehrazin R, Mazzone E, Marcus J, Danno A, Porter J, Asghar A, Ghali F, Guruli G, Douglawi A, Cacciamani G, Ghoreifi A, Simone G, Margulis V, Ferro M, Tellini R, Mari A, Srivastava A, Steward J, Al-Qathani A, Al-Mujalhem A, Bhattu AS, Mottrie A, Abdollah F, Eun DD, Derweesh I, Veccia A, Autorino R, Wang L. Wu Z, et al. Among authors: douglawi a. Eur Urol Focus. 2022 Jan;8(1):173-181. doi: 10.1016/j.euf.2021.01.014. Epub 2021 Feb 3. Eur Urol Focus. 2022. PMID: 33549537
Bladder Recurrence Following Diagnostic Ureteroscopy in Patients Undergoing Nephroureterectomy for Upper Tract Urothelial Cancer: Is Ureteral Access Sheath Protective?
Douglawi A, Ghoreifi A, Lee R, Yip W, Seyedian SSL, Ahmadi H, Cai J, Miranda G, Yu W, Bhanvadia S, Schuckman A, Desai M, Aron M, Sotelo R, Gill I, Daneshmand S, Fuchs G, Djaladat H. Douglawi A, et al. Urology. 2022 Feb;160:142-146. doi: 10.1016/j.urology.2021.11.026. Epub 2021 Dec 18. Urology. 2022. PMID: 34929237
Safety and feasibility of urological procedures in Jehovah's Witness patients.
Han J, Ahmadi H, Ladi-Seyedian SS, Clifford TG, Douglawi A, Xu W, Bazargani ST, Mingo S, Thangathurai D, Daneshmand S, Djaladat H. Han J, et al. Among authors: douglawi a. Int J Urol. 2022 Jan;29(1):83-88. doi: 10.1111/iju.14721. Epub 2021 Oct 12. Int J Urol. 2022. PMID: 34642972
20 results